Exploring the Impact of 3,3'-diindolylmethane on the Urinary Estrogen Profile of Premenopausal Women

Overview

Journal BMC Complement Med Ther

Publisher Biomed Central

Specialty Rehabilitation Medicine

Date 2024 Nov 23

PMID 39578798

Authors

Mark Newman

Jaclyn Smeaton

Affiliations

Soon will be listed here.

Abstract

Background: 3,3'-diindolylmethane (DIM) is a phytonutrient derived from cruciferous vegetables that is an often-used supplement in the complementary and alternative medicine space. The most common goal for providers when recommending DIM to their patients is to alter estrogen metabolism, yet research into DIM's effect on the estrogen profile is lacking in the published literature. The objective of this study was to comprehensively evaluate DIM's effect on the urinary estrogen profile.

Methods: In this retrospective cohort study, we analyzed data from a clinical laboratory, including urinary estrogen and estrogen metabolite concentrations. Analyte concentrations were determined from dried urine samples using a gas chromatography-tandem mass spectrometry assay. Individuals were separated into two groups, either reporting taking DIM (N = 909) or reporting not taking DIM (N = 18,385). Comparisons between individuals in these two groups were made using the Wilcoxon rank sum test. Additionally, we were also able to explore a subset of women who had laboratory results in the database before and after initiating DIM treatment (N = 53). In this subset, differences were assessed with Wilcoxon signed rank tests.

Results: In the larger group that was separated into women reporting either DIM use or no use, significant differences were observed in the concentrations of almost every urinary estrogen and estrogen metabolite (with the only exception being 2-methoxyestrone) in the urinary estrogen profiles of those taking DIM compared to those not taking DIM (all P values < 0.001). In the smaller subset of individuals with results before and after initiating DIM use, differences were only seen in 4 of the urinary estrogens and estrogen metabolites (P < 0.001 for estrone, estradiol, estriol, and 16-hydroxyestrone). Differences in total estrogens were significant in both the larger group and the smaller subset (both with P < 0.001). Additionally, observed differences in the ratios of metabolites followed a similar trend with more significant differences observed in the larger group. Notably, the 2-hydroxyestrone:16-hydroxyestrone ratio increased significantly in both the larger group and the smaller subset with results before and after DIM use.

Conclusions: The results of this study provide the most comprehensive evaluation to date of DIM's effect on the urinary estrogen profile. Additionally, the results demonstrate that the dried urine collection and accompanying assay used capture changes that are similar in direction, but not necessarily magnitude, to previous reports in the literature. Considered together, these two things highlight the clinical validity and utility of this approach to the evaluation of DIM supplementation and suggest the need for additional studies using this approach to fully understand the potential clinical utility of DIM.

References

Dalessandri K, Firestone G, Fitch M, Bradlow H, Bjeldanes L . Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004; 50(2):161-7. DOI: 10.1207/s15327914nc5002_5. View

Oredipe O, Barth R, Dwivedi C, Webb T . Dietary glucarate-mediated inhibition of initiation of diethylnitrosamine-induced hepatocarcinogenesis. Toxicology. 1992; 74(2-3):209-22. DOI: 10.1016/0300-483x(92)90140-a. View

Yerushalmi R, Bargil S, Ber Y, Ozlavo R, Sivan T, Rapson Y . 3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial. Carcinogenesis. 2020; 41(10):1395-1401. PMC: 7566319. DOI: 10.1093/carcin/bgaa050. View

Newman M, Curran D, Mayfield B, Saltiel D, Stanczyk F . Assessment of estrogen exposure from transdermal estradiol gel therapy with a dried urine assay. Steroids. 2022; 184:109038. DOI: 10.1016/j.steroids.2022.109038. View

Newman M, Pratt S, Curran D, Stanczyk F . Evaluating urinary estrogen and progesterone metabolites using dried filter paper samples and gas chromatography with tandem mass spectrometry (GC-MS/MS). BMC Chem. 2019; 13(1):20. PMC: 6661742. DOI: 10.1186/s13065-019-0539-1. View

Thomson C, Ho E, Strom M . Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr Rev. 2016; 74(7):432-43. PMC: 5059820. DOI: 10.1093/nutrit/nuw010. View

Williams D . Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane. Front Nutr. 2021; 8:734334. PMC: 8517077. DOI: 10.3389/fnut.2021.734334. View

Szaefer H, Licznerska B, Krajka-Kuzniak V, Bartoszek A, Baer-Dubowska W . Modulation of CYP1A1, CYP1A2 and CYP1B1 expression by cabbage juices and indoles in human breast cell lines. Nutr Cancer. 2012; 64(6):879-88. DOI: 10.1080/01635581.2012.690928. View

Newman M, Curran D . Reliability of a dried urine test for comprehensive assessment of urine hormones and metabolites. BMC Chem. 2021; 15(1):18. PMC: 7962249. DOI: 10.1186/s13065-021-00744-3. View

10.

Li C, Nguyen T, Chai O, Park B, Lee J, Kim S . 3,3'-Diindolylmethane Augments 5-Fluorouracil-InducedGrowth Suppression in Gastric Cancer Cells through Suppression of the Akt/GSK-3 and WNT/Beta-Catenin. J Oncol. 2023; 2023:8268955. PMC: 9922186. DOI: 10.1155/2023/8268955. View

11.

Newman M, Saltiel D, Smeaton J, Stanczyk F . Comparative estrogen exposure from compounded transdermal estradiol creams and Food and Drug Administration-approved transdermal estradiol gels and patches. Menopause. 2023; 30(11):1098-1105. PMC: 11896113. DOI: 10.1097/GME.0000000000002266. View

12.

Thomson C, Chow H, Wertheim B, Roe D, Stopeck A, Maskarinec G . A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 2017; 165(1):97-107. PMC: 5571834. DOI: 10.1007/s10549-017-4292-7. View

13.

Yang L, Zheng C, Xia Y, Dai Y, Wei Z . 3, 3'-diindolylmethane enhances macrophage efferocytosis and subsequently relieves visceral pain via the AhR/Nrf2/Arg-1-mediated arginine metabolism pathway. Phytomedicine. 2023; 116:154874. DOI: 10.1016/j.phymed.2023.154874. View

14.

de Kruif C, MARSMAN J, Venekamp J, Falke H, Noordhoek J, Blaauboer B . Structure elucidation of acid reaction products of indole-3-carbinol: detection in vivo and enzyme induction in vitro. Chem Biol Interact. 1991; 80(3):303-15. DOI: 10.1016/0009-2797(91)90090-t. View

15.

Tsuchiya Y, Nakajima M, Yokoi T . Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005; 227(2):115-24. DOI: 10.1016/j.canlet.2004.10.007. View

16.

Rajoria S, Suriano R, Parmar P, Wilson Y, Megwalu U, Moscatello A . 3,3'-diindolylmethane modulates estrogen metabolism in patients with thyroid proliferative disease: a pilot study. Thyroid. 2011; 21(3):299-304. PMC: 3048776. DOI: 10.1089/thy.2010.0245. View

17.

Godinez-Martinez E, Santillan R, Samano R, Chico-Barba G, Tolentino M, Hernandez-Pineda J . Effectiveness of 3,3'-Diindolylmethane Supplements on Favoring the Benign Estrogen Metabolism Pathway and Decreasing Body Fat in Premenopausal Women. Nutr Cancer. 2022; 75(2):510-519. DOI: 10.1080/01635581.2022.2123535. View

18.

Newman M, Mayfield B, Saltiel D, Stanczyk F . Assessing estrogen exposure from transdermal estradiol patch therapy using a dried urine collection and a GC-MS/MS assay. Steroids. 2022; 189:109149. DOI: 10.1016/j.steroids.2022.109149. View

19.

Tucci P, Brown I, Bewick G, Pertwee R, Marini P . The Plant Derived 3-3'-Diindolylmethane (DIM) Behaves as CB Receptor Agonist in Prostate Cancer Cellular Models. Int J Mol Sci. 2023; 24(4). PMC: 9962283. DOI: 10.3390/ijms24043620. View

20.

Anderton M, Manson M, Verschoyle R, Gescher A, Steward W, Williams M . Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004; 32(6):632-8. DOI: 10.1124/dmd.32.6.632. View